A comprehensive training program for clinical research coordinators. ICH-GCP aligned, FDA compliant, and designed for operational excellence.
NAVIGATE YOUR TRAINING
Comprehensive CRC training covering end-to-end competencies, SOPs, and regulatory requirements.
PRN is a site network. Individual research sites (such as Prolato Clinical Research Center) operate under the PRN umbrella with shared regulatory, recruitment, and operational infrastructure.
Overview: Clinical research evaluates the safety, efficacy, and outcomes of investigational drugs, devices, biologics, or procedures in human subjects. This section covers the foundations every CRC must know before working on any study.
By the end of this section, you should be able to: Understand the clinical research lifecycle, differentiate study types and phases, and describe the CRC role within the research team.
Clinical research is any research study that involves human subjects and is designed to evaluate the safety, efficacy, or outcomes of an intervention, diagnostic tool, or behavioral change. It is the bridge between laboratory discovery and real-world patient care.
| Type | Description | Key Characteristics |
|---|---|---|
| Interventional | Actively assigns participants to receive a specific intervention per protocol | Controlled, randomized, blinded; strongest evidence level |
| Observational | Evaluates outcomes without assigning any intervention; participants receive routine care | Natural history, cohort, case-control studies |
| Investigator-Initiated | Designed, initiated, and led by a physician or researcher, not a commercial sponsor | Investigator assumes primary responsibility; may have less sponsor support |
| Industry-Sponsored | Funded and managed by pharma, biotech, or device companies for product development | Rigorous protocols; supports regulatory approval (NDA/BLA/PMA) |
| Government-Funded | Supported by NIH, CDC, VA, or DoD; focus on public health priorities | Often addresses unmet medical needs or rare diseases |
Goal: Evaluate safety, tolerability, pharmacokinetics, and find safe dosing range.
Subjects: 20–80, often healthy volunteers.
Goal: Evaluate efficacy, optimal dosing, and side effect profile.
Subjects: 100–300 patients with the condition.
Goal: Confirm efficacy, monitor side effects, compare to standard of care. Basis for FDA approval.
Subjects: Hundreds to thousands. Multi-center.
Goal: Monitor long-term safety, detect rare adverse events, evaluate real-world outcomes after FDA approval.
Subjects: Large populations in routine clinical practice.
The CRC is the operational backbone of a clinical trial. You are the link between the investigator, the sponsor, the IRB, and the research subject.
Scheduling visits, obtaining consent, ensuring subject safety and retention
Maintaining binders, submitting documents to Regulatory Department
Enter and reconcile data in EDC and CTMS systems, source documentation, query resolution
Prepare for and participate in monitoring visits and SIVs, follow protocol procedures, support IP administration
Communicate effectively with monitors, sponsors, patients, and investigators
Protocol adherence, AE/SAE reporting, deviation documentation
A clinical trial involves many people with distinct roles. Understanding who does what — and who you report to — is critical from Day 1.
| Role | Who They Are | What They Do | Your Interaction |
|---|---|---|---|
| Principal Investigator (PI) | Licensed physician at the site | Ultimately responsible for all study conduct at the site. Signs 1572, makes medical decisions, reviews AEs, provides oversight | Report safety events, get medical decisions, ensure PI signs required documents |
| Sub-Investigator (Sub-I) | Physician, NP, PA, or PharmD | Performs delegated medical tasks under PI oversight. May conduct exams, assess AEs, sign orders | Daily clinical collaboration, performing protocol-required medical assessments |
| Clinical Research Coordinator (CRC) | You | Day-to-day study operations: consent, visits, data entry, documentation, binder maintenance, subject management | Everyone — you are the hub of the study |
| Lead Coordinator | Senior CRC at the site | Supervises CRCs, ensures quality, serves as first line of escalation, mentors new coordinators | Your direct supervisor and primary resource for questions |
| Clinical Research Associate (CRA/Monitor) | Sponsor or CRO representative | Monitors data, verifies source, conducts monitoring visits, writes follow-up letters | Prepare for visits, provide documents, address findings |
| Sponsor | Company or org funding the study | Owns the study. Provides protocol, IP, funding. Responsible for regulatory submissions to FDA | Indirect; via CRA or sponsor calls. Report SAEs directly per protocol |
| CRO (Contract Research Organization) | Company hired by sponsor | Manages operations on sponsor’s behalf: monitoring, data management, pharmacovigilance, project management | CRA and project managers are often CRO employees |
| IRB | Independent ethics committee | Reviews and approves research to protect human subjects. Must approve protocol, ICF, recruitment materials, amendments | Prepare submissions (with Regulatory Dept), report deviations and SAEs per IRB timelines |
| Research Pharmacist | Licensed pharmacist at site | Manages IP: receipt, storage, preparation, dispensing, accountability, destruction | Coordinate IP dispensing, report temperature excursions, reconcile accountability logs |
| Research Nurse | RN with research training | Administers IP (infusions, injections), draws labs, performs clinical assessments per protocol | Coordinate visit procedures, ensure nurse completes required documentation |
| Data Manager | Sponsor/CRO data team | Designs eCRF, generates data queries, monitors data quality, prepares database for lock | Resolve data queries, attend data review calls |
| Regulatory Department | PRN network-level team | Manages all IRB submissions, maintains regulatory files, ensures compliance across sites | Send documents for filing, coordinate submissions, escalate regulatory questions |
Understanding where clinical trials fit in the overall drug development process helps CRCs appreciate the significance of their work and why precision matters at every step.
| Stage | What Happens | Key Milestones |
|---|---|---|
| Discovery | Scientists identify a disease target (protein, receptor, gene) and screen thousands of compounds for activity against it | Lead compound identified |
| Pre-Clinical | Lab studies (in vitro) and animal studies (in vivo) to evaluate safety, toxicity, pharmacokinetics, and mechanism of action | Safety data package compiled |
| IND Application | Sponsor files Investigational New Drug application with FDA. Includes pre-clinical data, proposed clinical protocol, manufacturing info | FDA has 30 days to respond; if no “clinical hold,” trials may begin |
| Phase I–III | Human clinical trials (see Section 1.2). This is where you work. | Safety data, efficacy data, dose optimization |
| NDA/BLA Filing | Sponsor submits all clinical data to FDA for marketing approval. NDA = drugs; BLA = biologics; PMA = devices | FDA review, Advisory Committee meetings, approval/rejection/CRL |
| Post-Market (Phase IV) | Ongoing safety monitoring, label expansion studies, real-world evidence gathering | REMS, post-marketing commitments, label updates |
You will encounter these terms daily. Master them before your first study.
| Term | Definition |
|---|---|
| Randomization | Random assignment of subjects to treatment groups to reduce bias |
| Blinding | Concealing treatment assignment from subjects (single-blind), or subjects AND investigators (double-blind) |
| Placebo | An inactive substance or treatment used as a comparator to the investigational product |
| Standard of Care (SOC) | The current accepted treatment for a condition; often used as the active comparator arm |
| Inclusion Criteria | Characteristics a person MUST have to be eligible for the study |
| Exclusion Criteria | Characteristics that DISQUALIFY a person from participation |
| Washout Period | Time required between stopping a prior medication and starting the study drug |
| Visit Window | The acceptable date range for conducting a study visit (e.g., Day 28 ± 3 days) |
| Screen Failure | A subject who consents but does not meet all eligibility criteria |
| Term | Definition |
|---|---|
| Endpoint | The measurable outcome the study is designed to evaluate (primary endpoint = main outcome) |
| Arm | A treatment group within a study (e.g., treatment arm vs. placebo arm) |
| Cohort | A group of subjects enrolled together, often in dose-escalation studies |
| Concomitant Medication | Any medication taken by the subject in addition to the study drug (tracked at every visit) |
| Investigator Brochure (IB) | Comprehensive document with all known clinical and pre-clinical data about the investigational product |
| Source Document | The original record where clinical data is first captured (notes, lab printouts, ECGs) |
| Query | A question from the data manager about a data entry that appears inconsistent, missing, or incorrect |
| Database Lock | The point when the study database is finalized and no further changes can be made |
| Unblinding | Revealing treatment assignment; done only for safety emergencies per protocol procedures |
Every clinical trial depends on a team of professionals with clearly defined responsibilities. Understanding each role — and how they interact — ensures smooth operations, regulatory compliance, and subject safety.
By the end of this section, you should be able to: Identify all key roles on a clinical trial team, describe each role’s primary responsibilities, and understand the reporting and collaboration structure.
The Principal Investigator bears overall responsibility for conduct of the clinical trial at the site.
Study Coordinators should report safety events immediately, obtain medical decisions for eligibility and adverse events, ensure the PI signs all required documents, and keep the PI informed of monitoring visit findings.
The Nurse Practitioner acts as key personnel to ensure patient safety and protocol compliance during a study. At Provecta sites, NPs serve as sub-investigators under the PI’s oversight.
The Study Coordinator performs and supports daily study operations. You are the operational backbone of the clinical trial at the site and serve as the central point of contact for all stakeholders.
Lead Coordinators are senior SCs who oversee other coordinators at the site and bridge operations between the study team and site leadership.
Coordinators may only perform duties that are:
The Recruiter supports patient enrollment in clinical trials, maintaining professionalism and respect at all times.
Regulatory staff support study startup, maintenance, and closeout by ensuring compliance with applicable regulations, sponsor requirements, and IRB policies.
As the front desk representative, you are the face of Provecta Research Network and the first person patients and staff will see when they walk in. You have the responsibility to be respectful, friendly, and professional at all times. Represent us well!
Ensure all patient rooms are clean and ready. Stock all room caddies with required supplies:
When patients, monitors, or doctors enter the clinic, immediately send a message to the office (general notification) and the specific personnel the visit pertains to (make sure to tag).
You are responsible for managing all incoming calls and being a friendly, helpful voice for Provecta.
| Category | Items to Stock |
|---|---|
| Restroom Supplies | Paper towels, toilet paper, hand soap, hand sanitizer |
| Cleaning Supplies | Lysol, disinfectant spray, Clorox, Cavi Wipes |
| Office Supplies | Pens, sticky notes, notepads, tissue boxes, gloves |
| Kitchen Supplies | Plates, coffee cups, dish soap, napkins, utensils, K-cups, creamer, sugar |
| Patient Supplies | Snacks (granola bars, mints), Prolato folders |
| Medical Supplies | Butterfly needles (green/blue), bandages, surgical tape, alcohol wipes, tourniquets, gauze, stress balls |
| Task Area | Key Actions |
|---|---|
| Morning | Open facility, check ClinCompanion, prep rooms, stock supplies |
| Patient Arrival | Greet with smile, escort inside, offer refreshments, notify coordinator |
| Desk Coverage | NEVER leave unattended — arrange coverage before stepping away |
| IP Packages | Stop temperature monitor immediately, then notify coordinator |
| Supply Checks | Monthly inventory, request restocks BEFORE items run out |
| End of Day | Clean all areas, reminder calls, lock up, confirm package pickup |
| Time Off | Email Patti 1 week ahead; sick days text Patti + Lead Recruiter |
The following roles are external to Provecta Research Network but are essential to the conduct of every clinical trial. All PRN staff should understand who these stakeholders are and how they interact with our sites.
The CRA is the sponsor’s or CRO’s representative who monitors the site to ensure data quality, protocol adherence, and subject safety. They are one of your most frequent external contacts.
The Sponsor is the organization (pharmaceutical company, biotech, or academic institution) that initiates, funds, and manages the clinical trial.
A CRO is hired by the sponsor to perform some or all study management activities. Many CRAs, project managers, and data managers are CRO employees.
The IRB is an independent ethics committee that reviews all research involving human subjects. Their mission is to protect the rights, safety, and welfare of participants.
All task delegation at Provecta Research Network must follow these requirements:
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials involving human subjects. Compliance with GCP provides public assurance that the rights, safety, and well-being of trial subjects are protected and that clinical trial data is credible.
The current standard is ICH E6(R2), with E6(R3) being phased in. GCP applies to all clinical investigations that are intended to support regulatory submissions.
Every CRC must know these foundational principles:
| # | Principle |
|---|---|
| 1 | Clinical trials should be conducted in accordance with ethical principles from the Declaration of Helsinki and consistent with GCP and applicable regulatory requirements. |
| 2 | Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit. A trial should be initiated only if the anticipated benefits justify the risks. |
| 3 | The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society. |
| 4 | The available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial. |
| 5 | Clinical trials should be scientifically sound and described in a clear, detailed protocol. |
| 6 | A trial should be conducted in compliance with the protocol that has received prior IRB/IEC approval. |
| 7 | The medical care given to and decisions made on behalf of subjects should always be the responsibility of a qualified physician or dentist. |
| 8 | Each individual involved in conducting a trial should be qualified by education, training, and experience to perform their respective tasks. |
| 9 | Freely given informed consent should be obtained from every subject prior to clinical trial participation. |
| 10 | All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification. |
| 11 | The confidentiality of records that could identify subjects should be protected, respecting privacy and confidentiality rules. |
| 12 | Investigational products should be manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol. |
| 13 | Systems with procedures that assure the quality of every aspect of the trial should be implemented. |
U.S. Food & Drug Administration
Institutional Review Board
Study Owner & Operations
| Regulation | Scope | Why It Matters for CRCs |
|---|---|---|
| 21 CFR Part 50 | Informed Consent | Defines all required elements of informed consent; governs consent process |
| 21 CFR Part 56 | IRBs | Defines IRB composition, function, review requirements |
| 21 CFR Part 312 | IND Regulations | Governs investigational new drug applications and clinical trial conduct |
| 21 CFR Part 812 | IDE Regulations | Governs investigational device exemptions |
| 45 CFR Part 46 | Human Subjects (Common Rule) | HHS regulations for protection of human subjects in research |
| ICH E6(R2/R3) | Good Clinical Practice | International standard for trial conduct, documentation, reporting |
| HIPAA Privacy Rule | Protected Health Information | Governs use and disclosure of PHI in research |
| Declaration of Helsinki | Ethical Principles | Foundation of ethical research conduct worldwide |
CRCs work closely with the Regulatory Department to prepare IRB submissions. Understanding the different submission types helps ensure timely and accurate regulatory compliance.
| Submission Type | When Required | Key Elements |
|---|---|---|
| Initial Review | Before any study activities begin at the site | Protocol, ICF, investigator brochure, recruitment materials, FDA 1572, CVs, financial disclosures, CITI certificates |
| Continuing Review | At least annually (or per IRB-specified interval) to maintain approval | Progress report, enrollment numbers, AE/SAE summary, protocol deviations, current consent form, any changes since last review |
| Amendments | Any change to protocol, ICF, recruitment materials, or study procedures | Summary of changes, tracked-change documents, rationale for changes, updated consent if applicable |
| Reportable Events | Unanticipated problems, serious AEs, protocol deviations that affect safety or rights | Event description, impact assessment, corrective actions taken, within IRB-specified reporting timeline |
| Study Closure | When the study is complete or terminated at the site | Final enrollment summary, reason for closure, disposition of all subjects, plan for ongoing subject care, data/record retention plan |
A clinical trial protocol is the official, IRB-approved document that defines exactly how a study must be conducted. All study activities must follow the protocol as written. The protocol is not guidance — it is mandatory.
Protocols can be 100+ pages. Here is the order in which a new CRC should read and study a protocol:
| Read Order | Section | Why Read It First |
|---|---|---|
| 1 | Protocol Synopsis (1–3 pages) | Executive summary of the entire study: objectives, design, population, endpoints, visit schedule. Gives you the full picture in minutes. |
| 2 | Schedule of Events / Assessments (SOA) | The single most important table for CRCs. Shows every procedure at every visit. You will reference this at every single visit. |
| 3 | Inclusion / Exclusion Criteria | Determines who can enroll. Memorize the key criteria. I/E errors cause protocol violations. |
| 4 | Study Procedures (visit-by-visit) | Detailed description of what happens at each visit: timing, order, special requirements. |
| 5 | Safety: AE/SAE Definitions & Reporting | Know the reporting timelines. SAEs usually require 24-hour notification. Your response time matters. |
| 6 | IP Management | Dosing, administration, storage, accountability, and compliance. Mistakes here = major deviations. |
| 7 | Study Design & Objectives | Understand randomization, blinding, arms, endpoints. Helps you understand why procedures matter. |
| 8 | Everything Else | Statistical considerations, discontinuation criteria, data management, regulatory requirements. |
The protocol defines what the study is trying to prove and how success is measured.
The protocol outlines how the study is structured.
Defines who may and may not participate. Includes medical history, labs, medications, timelines.
Details what happens at each visit — required procedures, order, timing, and frequency.
Controls how study drug/device is managed: dosing, administration, storage, accountability, and compliance tracking.
Defines how subject safety is monitored — adverse event (AE) and serious adverse event (SAE) definitions, reporting timelines, and documentation.
Ensures data integrity through source documentation requirements and eCRF completion.
Explains how to handle non-compliance. Documentation and reporting requirements:
Follow IRB-specified reporting timelines and formats.
What it is: The legal and ethical agreement between the study team and the subject. Informed consent is not just a form — it is an ongoing process of communication.
Minor Subjects (Ages 7–17):
Non-English Speakers:
Informed consent is not just a signature on a form — it is a conversation. The goal is genuine understanding, not just legal compliance. Here is exactly how to conduct informed consent:
Find a private, quiet space. Ensure the subject is comfortable and not rushed. Have the correct, current IRB-approved ICF version ready. Confirm the subject can read and understand the language of the consent. If not, arrange a certified interpreter.
Explain in plain language: “This is a research study, not standard medical care.” Describe the purpose of the study, the investigational product, and what participation involves. Avoid medical jargon. Use analogies if helpful.
Go through every section of the consent form with the subject — do not hand them the form and wait. Key areas to emphasize: study procedures, risks and side effects, time commitment, alternatives to participation, right to withdraw at any time without penalty, confidentiality protections, compensation (if any), and who to contact with questions.
Ask open-ended questions: “Can you tell me in your own words what this study involves?” “What do you understand about the risks?” “Do you know you can stop at any time?” If the subject cannot articulate the key points, re-explain. Never rush this step.
The subject may take the ICF home to review with family or their personal physician. This is their right. Encourage questions. Answer honestly — if you don’t know, say “Let me find out for you” and follow up. Never minimize risks or overstate benefits.
Subject signs and dates. Person obtaining consent signs and dates. PI (or designee) signs if required by the protocol. Ensure all pages are initialed if the ICF requires it. Verify there are no blank signature lines.
Give the subject a signed copy immediately. File the original in the subject’s research record. Document the consent process in the subject’s chart: who was present, how long the discussion took, what questions were asked, and that the subject appeared to understand.
What they are: Proof the study is authorized by the reviewing IRB.
What it is: The investigator’s agreement with the FDA. The PI commits to conducting the trial per protocol and regulatory requirements.
What they are: Proof of investigator qualifications.
What it is: Documents who is authorized to do what on the study. Signed by the PI.
What they are: Proof that staff are qualified to perform delegated study tasks.
What they are: Reports of serious risks — sponsor safety reports, DSMB reports, IND Safety Reports.
What they are: Conflict-of-interest disclosures required by FDA (21 CFR Part 54).
The regulatory binder (also called the Investigator Site File or ISF) is a comprehensive collection of all essential documents for a clinical trial. The binder must be organized, current, and accessible at all times for monitoring visits, audits, and inspections.
| Tab / Section | Contents |
|---|---|
| Protocol & Amendments | Current protocol version, all amendments (with IRB approval for each), protocol signature page |
| Informed Consent Forms | All IRB-approved ICF versions (including translated versions), approval letters for each version |
| IRB Correspondence | Initial approval, continuing review approvals, amendment approvals, all IRB correspondence, IRB roster/FWA documentation |
| FDA Form 1572 | Current signed 1572, previous versions (if updated), list of sub-investigators |
| CVs & Medical Licenses | PI and all sub-investigators — signed, dated, current (within 2 years) |
| Financial Disclosures | Completed forms for all personnel on FDA 1572 |
| Delegation of Authority Log | Current DOA log signed by PI, training documentation for all delegated tasks |
| Training Records | GCP certificates, protocol training logs, CITI certificates, study-specific training records |
| Lab Certifications | CAP/CLIA certificates, lab normal ranges, lab director CV |
| Investigator Brochure | Current IB and all updates, acknowledgment of receipt |
| Safety Reports | IND Safety Reports, SUSAR notifications, DSMB reports, acknowledgment of receipt for each |
| Monitoring Visit Logs | Monitoring visit log, follow-up letters, site response letters |
| IP Documentation | IP receipt records, temperature logs, destruction certificates, accountability logs |
| Recruitment Materials | IRB-approved advertisements, flyers, scripts (with IRB approval documentation) |
| Correspondence | Sponsor correspondence, CRO communications, regulatory authority correspondence |
| Site-Specific Documents | Site agreements/contracts, insurance certificates, facility certifications |
Subject management encompasses everything from initial contact through study completion or discontinuation. This section covers the CRC’s role at every stage of the subject lifecycle, including HIPAA compliance, screening, enrollment, visits, and retention.
The Health Insurance Portability and Accountability Act (HIPAA) governs the use and disclosure of Protected Health Information (PHI). As a CRC, you handle PHI every day. Violations carry severe consequences.
PHI is any individually identifiable health information. In research, this includes:
Name, address, phone, email, SSN, MRN, DOB, photos
Diagnoses, lab results, medications, treatment history, provider notes
Enrollment status, visit dates, AE reports, specimen data linked to identifiers
| Do | Never |
|---|---|
| Use subject IDs (not names) on all study documents | Discuss subject information in public areas |
| Store paper records in locked cabinets | Leave charts, lab results, or monitors unattended |
| Use encrypted email for PHI transmission | Send PHI via unencrypted personal email or text |
| Shred documents containing PHI before disposal | Throw PHI documents in regular trash |
| Lock your computer when stepping away | Share login credentials with anyone |
| Collect only the minimum necessary PHI | Access medical records for subjects not on your studies |
Pre-screening activities are conducted prior to the main screening visit to determine whether a potential subject may meet key protocol eligibility criteria. Pre-screening does not constitute enrollment.
Review electronic/paper medical records
When records unavailable or protocol requires
Obtain limited info for basic eligibility
Purpose: To describe the process for screening research subjects for COVID-19 at PRN sites.
All subjects are screened via phone before their scheduled visit. Subjects are asked:
Effective recruitment is critical to study success. Enrollment delays are the #1 reason clinical trials exceed their timelines and budgets. CRCs play a key role in working with the Recruitment Department to identify and engage potential participants.
Review EMR/EHR systems for patients meeting key I/E criteria
Partner with treating physicians to identify eligible patients
Health fairs, support groups, community presentations
| Challenge | Strategies to Address |
|---|---|
| Narrow eligibility criteria | Cast a wider referral net; work with the Recruitment Department to expand outreach channels |
| Competing studies | Differentiate study benefits; maintain strong physician relationships |
| Patient fears/misconceptions | Education-first approach; provide clear, honest study information |
| Transportation barriers | Offer travel reimbursement; consider telemedicine options per protocol |
| Schedule conflicts | Offer flexible scheduling windows; accommodate work/family needs when possible |
“Good morning/afternoon. My name is [Recruiter’s Name] calling from Dr. Mandayam’s office at Prolato Clinical Research Center. May I please speak with [Patient’s Name]?”
“I’m reaching out because you previously inquired about participating in our clinical research studies. Do you have a few minutes to go over the clinical trial process?”
All clinical trials are free of charge; no insurance or payment will be requested. Compensation depends on the study and visit.
“Every study has different criteria. Is it okay if I ask you a few questions regarding your medical history to determine which study you pre-qualify for?”
“Based on your medical history, you may qualify for the [Study Name] study. This study involves [brief description: duration, visit frequency, procedures]. Compensation is [amount], paid [per visit / total].”
Schedule the visit, send appointment details by email/text, and arrange a reminder call the day before.
If transportation is a concern, assistance may be arranged depending on the study sponsor. Mileage reimbursement is also available.
| Indication | ICD-10 Code |
|---|---|
| Graves’ Disease | E05.00, E05.01 |
| Atopic Dermatitis | L20.0–L20.9 |
| Alzheimer’s Disease | G30.0, G30.1, G30.8, G30.9 |
| Dementia | F03.90, F01.50, F02.80 |
| Chronic Kidney Disease | N18.1–N18.6 |
| IgA Nephropathy | N02.B–N03.B |
| Primary Membranous Nephropathy | N03.2 |
| FSGS | N04.1, N05.1, N06.1 |
| Systemic Lupus (SLE) | M32.0–M32.9 |
| Lupus Nephritis | M32.14, M32.15 |
| Diabetic Kidney Disease | E08.22–E11.22 |
| Gout | M10.0–M10.9 |
| Rheumatoid Arthritis | M05.x, M06.x |
| Sjogren’s Syndrome | M35.00–M35.09 |
| Myasthenia Gravis | G70.00, G70.01 |
| Hypercholesterolemia | E78.00, E78.01 |
| ANCA-Associated Vasculitis | M31.30, M31.31, M30.1 |
| Primary Biliary Cholangitis | K74.3 |
| Axial Spondyloarthritis | M45.x, M46.8 |
The screening visit determines whether a subject qualifies for enrollment. It is one of the most procedure-heavy visits and requires meticulous documentation.
| Step | Action | Critical Details |
|---|---|---|
| 1 | Verify informed consent | Correct ICF version, all signatures and dates present, subject received a copy, process documented in chart |
| 2 | Collect demographics | DOB, sex, race/ethnicity (per protocol), contact info, emergency contacts, PCP information |
| 3 | Medical history | Complete medical, surgical, and family history. Document ongoing conditions and resolved conditions. Be thorough — missed history can affect eligibility or safety assessments later. |
| 4 | Concomitant medications | Record ALL current medications — prescription, OTC, vitamins, supplements, herbal. Include dose, route, frequency, indication, and start date. Check against exclusion criteria for prohibited medications. |
| 5 | Physical exam | Performed by PI or Sub-I. CRC coordinates timing and documents results. Note any clinically significant findings. |
| 6 | Vital signs | BP, HR, RR, temperature, weight, height (per protocol). Document position (sitting/standing), arm used, equipment ID, and timing relative to other procedures. |
| 7 | ECG (if required) | 12-lead ECG per protocol specifications. Document time, result, PI assessment (normal/abnormal/clinically significant). |
| 8 | Laboratory assessments | Draw labs per protocol. Verify correct tubes, labels (subject ID, date, time), and processing requirements. Ship per kit instructions. |
| 9 | Verify I/E criteria | Systematically check every inclusion and exclusion criterion. Document the assessment. If any criterion is not met, the subject is a screen failure. |
| 10 | Complete source & eCRF | Document all procedures performed, results, and I/E assessment. Enter data in EDC. Schedule the next visit if eligible. |
Purpose: Standard operating procedure for checking and documenting vital signs on all subjects at each visit.
| Vital Sign | Key Requirements |
|---|---|
| Temperature | Document method and device used |
| Heart Rate | Count for full 60 seconds if irregular |
| Respiratory Rate | Count without subject’s awareness if possible |
| Blood Pressure | Validated, calibrated device; correct cuff size; arm at heart level. At first visit, measure both arms — use higher-reading arm for subsequent visits. Separate repeated measurements by 1–2 minutes. |
| Oxygen Saturation | Pulse oximetry per protocol requirements |
| Pain Score & Mental Status | As appropriate per protocol |
Purpose: To describe procedures for establishing and maintaining site blinding for the study drug.
Purpose: Standards for administration of study medication through intravenous (IV) route with consideration for patient safety, comfort, and protocol requirements.
Purpose: Procedure for management of occluded central venous access devices (CVADs) — multipurpose catheters used for vascular access ending in a large central vein.
| Type | Cause | Response |
|---|---|---|
| Thrombotic | Thrombus within, surrounding, or at tip of catheter | Suspect after ruling out mechanical obstruction and medication precipitation |
| Non-Thrombotic | Precipitates, mal-positioning, mechanical obstructions | Examine tubing/extension/connector; reposition patient; review medication incompatibilities |
Follow manufacturer protocol for CVAD occlusion management.
Purpose: To outline procedures for investigational product handling, storage, and destruction.
Purpose: Temperature control is critical to ensure the safety, efficacy, and regulatory compliance of investigational products. This SOP provides standardized procedures for monitoring, documenting, and responding to temperature conditions across all PRN storage areas.
| Role | Responsibility |
|---|---|
| PI | Ensures compliance at site level; designates a Temperature Monitoring Representative (TMR) |
| TMR | Oversees daily monitoring, reviews reports, responds to alarms, coordinates corrective actions, maintains documentation |
| Study Staff | Record daily manual readings and report any abnormal values immediately |
| Quality Assurance | Conducts audits, reviews calibration and training records |
| Storage Type | Range (°C) | Range (°F) |
|---|---|---|
| Controlled Room | 20–25 °C | 68–77 °F |
| Refrigerator | 2–8 °C | 35.6–46.4 °F |
| −20 °C Freezer | −25 to −15 °C | −13 to 5 °F |
| −80 °C Freezer | −80 to −70 °C | −112 to −94 °F |
WiFi Logger for rooms, fridges, −20°C. Real-time cloud monitoring with SMS/email alarms.
Cryogenic Logger for −80°C ultra-low freezers. External probe, PDF via USB.
Manual backup thermometers for all units. Daily paper records and redundancy.
Purpose: Standardized procedures for transportation of study product to ensure integrity, accountability, and temperature control.
Purpose: Procedure for transportation of biological study samples between sites and to laboratories.
Subject retention is as important as recruitment. Losing participants during a trial compromises statistical power, delays study completion, and increases costs. Understanding why subjects drop out is the first step to preventing it.
| Tactic | How to Implement |
|---|---|
| Build Rapport Early | Establish a personal connection at screening/baseline. Learn names, show genuine interest, make subjects feel valued — not like a number. |
| Set Expectations Clearly | During consent, clearly explain the full timeline, visit requirements, potential side effects, and what participation entails. No surprises. |
| Appointment Reminders | Call or text 2–3 days before each visit. Send reminder cards. Confirm date, time, location, and any preparation needed (fasting, bringing medications, etc.). |
| Flexible Scheduling | Offer early morning, late afternoon, or weekend slots when protocol allows. Accommodate work and family schedules within visit windows. |
| Reduce Visit Burden | Organize visits efficiently. Minimize wait times. Group assessments logically. Respect the subject’s time. |
| Travel Support | Offer travel reimbursement, parking validation, or rideshare vouchers per sponsor/IRB-approved compensation plans. |
| Regular Check-ins | Contact subjects between visits to see how they’re doing. Address concerns before they become reasons to discontinue. |
| Address AEs Promptly | Take side effects seriously. Ensure PI reviews and manages AEs quickly. Subjects who feel heard about their discomfort are more likely to stay. |
| Celebrate Milestones | Acknowledge when subjects complete key visits (midpoint, end of treatment). A simple “thank you” goes a long way. |
| Emergency Contact Collection | Collect 2+ emergency contacts and a PCP at enrollment. Update contact info at each visit. Critical for preventing LTFU. |
Purpose: Standardized procedure for identifying, managing, documenting, and reporting subjects who are lost to follow-up.
Definition: LTFU is concluding participation prior to completing all protocol-required elements by a subject who has stopped attending visits and cannot be located.
ALCOA+ is the gold standard framework for data integrity in clinical research. Every piece of data you record must meet these criteria:
| Principle | Meaning | What This Looks Like in Practice |
|---|---|---|
| Attributable | Clear who performed the action and recorded the data | Includes signature/initials, date, and time |
| Legible | Data is readable and understandable | Entries are permanent and not obscured |
| Contemporaneous | Recorded at the time the activity or observation occurs | Late entries are clearly identified as such |
| Original | The data is the first capture (source data) | Or a certified true copy of the original record |
| Accurate | Correct and reflects what actually occurred | Errors corrected per GCP: single line-through, dated, initialed |
| Complete | All required data is present | Includes explanations for missing data, repeats, or deviations |
| Consistent | Follows logical chronological order | Information matches across all study records (source, eCRF, logs) |
| Enduring | Recorded in a durable medium | Protected from loss or unauthorized alteration |
| Available | Readily accessible for monitoring, audit, inspection | Retrievable for the full retention period |
| Document Type | What It Captures | Key Requirements |
|---|---|---|
| Visit-Specific Source Worksheets | All procedures performed at a visit: vitals, assessments, labs, AEs, conmeds, IP dosing | Completed in real time during the visit; must match eCRF exactly |
| Lab Printouts / Results | Central and local lab results, reference ranges, flags | Date stamped; PI must review and sign with assessment (CS/NCS) |
| ECG Tracings | 12-lead ECG rhythm strips with machine interpretation | Subject ID, date, time on tracing; PI reads and signs |
| Medical Records / Chart Notes | Progress notes, AE follow-up, concomitant med changes | Certified copies must be stamped “true and accurate copy” |
| Subject Diary / ePRO | Patient-reported outcomes: symptoms, medication compliance | Subject completes independently; CRC reviews for completeness at visits |
| AE/SAE Report Forms | Event description, onset/resolution dates, severity, causality, outcome | PI must assess causality; SAE forms submitted within protocol timelines |
| IP Accountability Log | Every IP transaction: receipt, dispensing, return, destruction | Running balance must reconcile; discrepancies reported immediately |
| Concomitant Medication Log | All meds taken during the study: name, dose, frequency, indication, dates | Updated at every visit; check against prohibited medication list |
| # | Mistake | How to Avoid It |
|---|---|---|
| 1 | Documenting hours or days after the event | Document in real time during or immediately after each procedure |
| 2 | Using white-out or scribbling out errors | Single line through, initial, date, brief reason — every time |
| 3 | Leaving fields blank without explanation | Write “N/A”, “Not Done”, or “Not Assessed” with a reason |
| 4 | Mismatch between source and eCRF | Enter eCRF data directly from source; verify before saving |
| 5 | Missing date or time on procedures | Every entry needs: who, what, when. Date and time are non-negotiable. |
| 6 | Not recording “nothing happened” | If a subject reports no AEs, document “Subject reports no new AEs” — negative findings matter |
| 7 | Using abbreviations not on the site’s approved list | Stick to protocol or site-approved abbreviations only |
| 8 | PI not reviewing and signing source | Establish a weekly source review process with the PI |
| 9 | Not documenting the consent discussion | Who was present, duration, questions asked, comprehension assessed |
| 10 | Copying data from eCRF back to source | Never. Source is the original. eCRF is transcribed FROM source. |
Purpose: Procedure for certifying medical records used as source documents in clinical research.
Database locks require strict data entry timelines
Data must match source documents exactly
Respond to data queries promptly and completely
eCRF data must be consistent with source
| System | Common Sponsors | Key Features |
|---|---|---|
| Medidata Rave | Large pharma, oncology studies | Most widely used globally. Robust query management, edit checks, e-signatures |
| Oracle Clinical / InForm | Large pharma & CROs | Flexible form design, strong audit trail, complex visit scheduling |
| Veeva Vault CDMS | Growing adoption across sponsors | Cloud-native, modern UI, integrated with Veeva clinical suite |
| REDCap | Academic, investigator-initiated | Free, web-based, commonly used in academic research and smaller studies |
| Florence eBinders | Various | Electronic regulatory binder system — not an eCRF but manages site documents |
Each system has unique navigation, but the principles are the same: source → eCRF, resolve queries, sign forms, maintain audit trail.
Queries are questions from the data management team about your eCRF entries. They flag potential errors, inconsistencies, or missing data. Resolving queries quickly and correctly is a core CRC skill.
| Query Type | Example | How to Respond |
|---|---|---|
| Missing Data | “Vital signs not entered for Visit 4” | Enter the data from source. If not collected, explain why (e.g., “Subject refused BP measurement”) |
| Inconsistency | “AE start date is before consent date” | Check source. Correct the date if wrong, or clarify (e.g., “Pre-existing condition documented at screening”) |
| Out of Range | “Heart rate 210 — please verify” | Check source. If correct, confirm: “Verified per source. Subject had tachycardia episode.” If wrong, correct it. |
| Logic Check | “End date before start date for conmed” | Review source, correct the error, note the reason for correction |
Tracking concomitant medications is one of the most time-consuming but critical CRC tasks. Every medication the subject takes — prescription, OTC, vitamins, supplements, herbal remedies — must be documented.
Clinical Research Associates (CRAs/Monitors) visit the site to verify data, review source documents, and ensure protocol compliance.
Purpose: Procedure for timely review and resolution of follow-up letters received after monitoring visits.
Use this checklist to prepare for each monitoring visit. Run through it at least 24 hours before the CRA arrives. Being well-prepared reduces findings and ensures efficient use of time on site.
| Visit Type | When | Purpose | CRC Preparation |
|---|---|---|---|
| Pre-Study / Qualification Visit | Before site selection | Sponsor evaluates if the site can conduct the study (facilities, staff, patient population) | Tour readiness, present capabilities, review potential enrollment |
| Site Initiation Visit (SIV) | Before first enrollment | Protocol training, regulatory review, systems setup, IP training (see Section 8.2) | All regulatory docs complete, staff available, systems ready |
| Interim Monitoring Visit (IMV) | Throughout the study (every 4–8 weeks) | Source data verification (SDV), document review, safety review, data cleaning | Subject binders organized, eCRF up to date, queries resolved, PI available for questions |
| Remote Monitoring | Between on-site visits | eCRF review, query resolution, safety data review, document requests | Upload requested documents, resolve outstanding queries, respond to emails promptly |
| Close-Out Visit (COV) | After last subject completes | Final data reconciliation, IP accountability, document archiving, binder handoff | All data entered and clean, all queries resolved, IP reconciled, binders complete |
| For-Cause Visit | Triggered by concern | Focused review prompted by compliance issues, data concerns, or safety signals | Address the specific concern transparently; do not alter documents |
The Site Initiation Visit (also called the Study Start-Up Visit or Investigator Meeting at Site) occurs before any subjects are enrolled. It is conducted by the sponsor or CRA to confirm the site is ready to begin enrollment.
Detailed walkthrough of the protocol, visit schedule, and procedures
Review of all essential documents (1572, DOA, CVs, IRB approval)
EDC training, IVRS/IWRS access, lab kit review
Storage, handling, dispensing, accountability procedures
Purpose: Procedures for study coordinator attendance at investigator meetings (IMs).
Your site may receive audits from sponsors (routine quality checks) or FDA inspectors (regulatory inspections under the BIMO program). The preparation and implications differ significantly.
| # | Finding |
|---|---|
| 1 | Failure to follow the investigational plan (protocol deviations) |
| 2 | Inadequate informed consent process |
| 3 | Inadequate drug accountability records |
| 4 | Failure to report adverse events |
| 5 | Inadequate or inaccurate case histories/source documents |
| 6 | Failure to maintain IRB oversight |
| 7 | Delegation of duties to unqualified individuals |
| 8 | Enrollment of ineligible subjects |
| 9 | Inadequate record retention |
| 10 | Failure to ensure proper IP storage conditions |
At PRN, QA is our blanket term for all quality-related activities — both preventing errors and catching them. Quality assurance ensures that clinical trials produce reliable data while protecting subject safety. Every CRC is expected to perform QA on their own work daily.
| Area | QA Action |
|---|---|
| Source Documents | Review for completeness, accuracy, and ALCOA+ compliance before filing |
| eCRF Data | Verify all entries match source. Resolve queries within sponsor timelines |
| Consent Forms | Verify correct version, all pages signed and dated, no blank fields |
| Regulatory Binder | Maintain current and organized. Conduct self-inspections quarterly |
| IP Accountability | Reconcile dispensing and return records. Verify temperature logs |
| Safety Reporting | Verify AE/SAE reports are complete, accurate, and submitted on time |
Purpose: Procedures for utilizing the PAT to monitor and document study coordinator activities at PRN sites, providing visibility into time allocation across clinical trials.
A protocol deviation is any unplanned departure from the IRB-approved protocol. Deviations range in severity and may or may not impact subject safety or data integrity.
Record immediately with all details
Inform Lead CRC and PI
Submit to sponsor and IRB
Implement corrective and preventive actions
When a CRC identifies a protocol deviation during study conduct, it is the primary CRC’s responsibility to:
When a monitor identifies a deviation during a monitoring visit and documents it in the follow-up letter, it is Regulatory’s responsibility to:
Addresses the current problem. What did you do to fix this specific deviation?
Prevents recurrence. What will you change to stop this from happening again?
Safety monitoring and adverse event reporting are among the most critical CRC responsibilities. Accurate classification ensures subject safety, regulatory compliance, and data integrity.
Any untoward medical occurrence in a subject, whether or not considered related to the investigational product.
An AE that meets any one of the following criteria:
The Common Terminology Criteria for Adverse Events (CTCAE) is the standard grading scale used in most clinical trials:
| Grade | Severity | Description | Examples |
|---|---|---|---|
| 1 | Mild | Asymptomatic or mild symptoms; no intervention needed | Mild headache, low-grade lab abnormality |
| 2 | Moderate | Minimal, local, or noninvasive intervention needed; limits daily activities | Persistent nausea requiring antiemetics |
| 3 | Severe | Significant but not immediately life-threatening; hospitalization may be needed | IV fluids required for dehydration |
| 4 | Life-Threatening | Urgent intervention required; consequences of death | ICU admission, septic shock |
| 5 | Death | Death related to adverse event | Fatal cardiac arrest |
For every AE, the investigator (PI) must assess whether it is related to the study treatment. CRCs collect the data; the PI makes the determination.
| Category | Definition |
|---|---|
| Definitely Related | Clear temporal relationship and no other explanation. Event resolves with drug discontinuation and recurs with re-challenge. |
| Probably Related | Reasonable temporal relationship, consistent with known drug profile, unlikely due to other causes. |
| Possibly Related | Temporal relationship exists, but other causes are equally plausible. |
| Unlikely Related | Temporal relationship is doubtful. Another cause is more likely. |
| Not Related | No temporal or causal relationship. Clearly attributable to another cause (e.g., pre-existing condition, concomitant medication). |
Purpose: Procedure for capturing and reporting adverse events (AE) and serious adverse events (SAE) at PRN sites.
Understanding the history of research ethics is not optional — it is foundational. Every protection we follow today — informed consent, IRB oversight, GCP guidelines, the Belmont Report — exists because real human beings were exploited, harmed, or killed when those protections did not exist. As a CRC, you are the direct inheritor of these lessons. Know them.
Concentration camp prisoners were subjected to forced medical experiments including hypothermia (submerging victims in ice water for hours), high-altitude decompression chambers, deliberate wound infection with bacteria, bone/muscle/nerve transplantation, forced sterilization, and exposure to mustard gas and poison. Subjects had no choice and thousands were killed or permanently maimed. At the Nuremberg Trials, 23 Nazi doctors were prosecuted. Their defense — “there were no rules” — led directly to the Nuremberg Code (1947), the first international document establishing that voluntary consent is absolutely essential and that experiments must avoid unnecessary suffering.
The U.S. Public Health Service enrolled 600 Black men in Macon County, Alabama — 399 with syphilis and 201 without — to study the natural progression of untreated syphilis. Subjects were told they were receiving free treatment for “bad blood,” but they never received treatment. They were given placebos, aspirin, and vitamins instead. When penicillin became the standard cure in 1947, researchers actively prevented subjects from receiving it — including intercepting draft notices that would have given them military medical treatment. The study continued for 40 years until journalist Jean Heller exposed it in the Associated Press in 1972. By then, 28 men had died directly of syphilis, 100 had died of related complications, 40 wives had been infected, and 19 children were born with congenital syphilis. This study led directly to the National Research Act of 1974, the creation of IRBs, and the Belmont Report. In 1997, President Clinton issued a formal apology on behalf of the U.S. government.
Henrietta Lacks was a 31-year-old Black woman treated for cervical cancer at Johns Hopkins Hospital in Baltimore. During a biopsy, Dr. George Gey took samples of her cancer cells without her knowledge or consent. These cells were remarkable — they were the first human cells to survive and reproduce indefinitely in a laboratory. Named “HeLa” cells, they became one of the most important tools in modern medicine, contributing to breakthroughs in the polio vaccine, cancer research, HIV/AIDS, gene mapping, in vitro fertilization, and countless drug trials.
Henrietta died on October 4, 1951, at age 31. Her family was never informed that her cells had been taken, never consented to their use, and never compensated — even as HeLa cells generated billions of dollars in medical research and pharmaceutical profits. Her family lived in poverty while corporations sold her cells for $25 per vial. Researchers even published her full genome without family consent in 2013.
The Lacks story highlights critical issues: tissue ownership rights, informed consent for biological specimens, racial inequity in research, and the gap between scientific advancement and ethical treatment of research subjects. In 2023, the Lacks family reached a settlement with Thermo Fisher Scientific. The NIH now requires researchers to obtain permission from the Lacks family to use the HeLa genome sequence.
Willowbrook was a severely overcrowded New York state institution for children with intellectual disabilities. Dr. Saul Krugman and his team deliberately infected newly admitted children with hepatitis by feeding them stool extracts from infected patients — to study the disease’s natural history and develop a vaccine. Parents were told their children would receive a “vaccine” and were coerced into signing consent: the only way to gain admission to the overcrowded facility was to enroll their child in the hepatitis unit, which had shorter waitlists. The researchers argued that children would “inevitably” contract hepatitis in the institution anyway. This case exposed the exploitation of vulnerable, institutionalized populations and demonstrated that “consent” obtained under duress is not true consent.
U.S. Public Health Service researchers, including some of the same individuals involved in Tuskegee, deliberately infected over 1,300 Guatemalan citizens — prisoners, soldiers, psychiatric patients, and sex workers — with syphilis, gonorrhea, and chancroid without their consent. Researchers used commercial sex workers known to be infected to spread disease to prisoners, and when that method proved “inefficient,” they inoculated subjects directly by pouring bacteria onto abraded skin and even performing spinal punctures. At least 83 subjects died. The experiments were hidden for over 60 years until historian Susan Reverby discovered them in 2010. President Obama personally apologized to the President of Guatemala.
Researchers at a family planning clinic in San Antonio gave Mexican-American women placebos instead of oral contraceptives without their knowledge, to study the side effects of birth control pills. The women believed they were receiving actual contraception. Ten women became pregnant during the study. The researchers never disclosed that some participants would receive inactive pills. This case underscored the principle that vulnerable and minority populations must not bear disproportionate research risks and that deception in research requires extraordinary justification and full IRB scrutiny.
Thalidomide was a sedative marketed by the German company Chemie Grünenthal as safe for morning sickness in pregnant women. It was sold over the counter in 46 countries. The drug had never been adequately tested for effects on fetal development. The result: over 10,000 children were born with severe birth defects — most commonly phocomelia (severely shortened or absent limbs), but also deafness, blindness, heart defects, and facial disfigurement. Approximately 40% of affected infants died within their first year. The United States was largely spared because FDA reviewer Dr. Frances Kelsey refused to approve the drug, demanding additional safety data — a decision that made her a national hero and earned her the President’s Award for Distinguished Federal Civilian Service. This tragedy led to the Kefauver-Harris Amendment (1962), requiring drug manufacturers to prove both safety and efficacy before marketing, and establishing the modern framework for FDA drug approval that governs every clinical trial you will work on.
| Framework | Year | Key Contribution |
|---|---|---|
| Nuremberg Code | 1947 | 10 principles: voluntary consent is absolutely essential; experiments must be for the good of society; avoid unnecessary suffering; subject can withdraw at any time |
| Declaration of Helsinki | 1964 | World Medical Association guidelines: subjects’ welfare takes precedence over interests of science and society; special protections for vulnerable populations; requires independent ethics committee review |
| National Research Act | 1974 | Created the National Commission for the Protection of Human Subjects; mandated IRB review for all federally funded research; direct response to Tuskegee |
| Belmont Report | 1979 | Three core principles: Respect for Persons (voluntary informed consent; protect those with diminished autonomy), Beneficence (maximize benefits, minimize harm; do no harm), Justice (fair distribution of research burdens and benefits across populations) |
| Common Rule (45 CFR 46) | 1991 | Federal regulations requiring IRB review and informed consent for all federally funded human subjects research; additional protections for pregnant women, prisoners, children |
| ICH-GCP E6 | 1996 | International standard harmonizing clinical trial conduct across the US, EU, and Japan; 13 principles; basis for modern site operations |
The Belmont Report is the ethical foundation of all human subjects research in the United States. Every CRC decision can be traced back to one of these three principles:
Individuals are autonomous agents capable of making their own decisions. Those with diminished autonomy (children, cognitively impaired, prisoners) deserve extra protection.
In your daily work: Informed consent process, right to withdraw, protecting decisional capacity, LAR consent, assent for minors
Do no harm. Maximize possible benefits and minimize possible harms. Research must have a favorable risk-benefit ratio.
In your daily work: Safety monitoring, AE/SAE reporting, dose modifications, stopping rules, protocol adherence
The benefits and burdens of research must be distributed fairly. No group should be exploited or excluded without scientific justification.
In your daily work: Fair recruitment, equitable eligibility criteria, not targeting vulnerable populations, ensuring diverse enrollment
Follow ICH-GCP guidelines in every action
Protect PHI per HIPAA at all times
Never fabricate, falsify, or back-date records
Clear, timely, respectful with all stakeholders
Subject safety and rights always come first
Stay current with regulations, protocols, and best practices
These are the most common errors observed across clinical research sites. Learning from others’ mistakes is one of the fastest ways to become an excellent CRC.
| # | Mistake | Why It’s a Problem | Prevention |
|---|---|---|---|
| 1 | Not reading the protocol thoroughly | Leads to missed procedures, wrong visit windows, eligibility errors | Read the full protocol before your first visit. Reread SOA before every visit. |
| 2 | Performing procedures before consent | Regulatory violation; can invalidate all data collected | Consent is ALWAYS Step 1. No exceptions. |
| 3 | Using an expired ICF version | FDA finding; requires re-consent and deviation report | Verify ICF version at every visit. File amendments immediately. |
| 4 | Not documenting in real time | Violates “Contemporaneous” in ALCOA+; questions data reliability | Document during or immediately after each procedure. |
| 5 | Enrolling an ineligible subject | Protocol violation; potential safety risk; data may be excluded | Check every I/E criterion. Have PI verify. Double-check labs. |
| 6 | Missing AE/SAE reporting timelines | Can result in FDA warning letter; compromises subject safety | Know your timelines (usually 24 hrs for SAE). Set calendar reminders. |
| 7 | Not asking about concomitant medications | Missed drug interactions; incomplete safety data | Ask at every visit. Ask specifically about OTC, vitamins, supplements. |
| 8 | Poor query resolution | Delays database lock; creates more work during monitoring | Resolve queries within 3–5 business days. Always reference source. |
| 9 | Disorganized regulatory binder | Top monitoring and audit finding; creates compliance risk | Update after every new document. Do monthly self-checks. |
| 10 | Not notifying PI of safety events | PI is legally responsible; they must assess and make medical decisions | Report AEs/SAEs to PI same day. Document notification. |
| 11 | Skipping visit window calculations | Out-of-window visits = protocol deviations | Calculate windows in advance. Put them in the subject’s calendar. |
| 12 | Not preparing for monitoring visits | Longer visits, more findings, site looks disorganized | Pre-monitor review: binders, source, eCRF, queries all current. |
| 13 | Being afraid to ask questions | Assumptions lead to errors | Ask your Lead CRC, PI, or CRA. No question is too basic when safety is involved. |
| 14 | Not collecting emergency contacts at enrollment | Cannot locate subject if they become LTFU | Get 2+ contacts, PCP info, and preferred communication method at screening. |
| 15 | Taking shortcuts under time pressure | Short-term convenience = long-term compliance problems | Do it right the first time. It always takes more time to fix than to do correctly. |
| Document | Purpose |
|---|---|
| Protocol | Defines how the study must be conducted |
| Informed Consent Forms | Legal/ethical agreement with subjects |
| FDA Form 1572 | Investigator's agreement with FDA |
| Delegation of Authority Log | Who can do what on the study |
| Training Logs | Proof of staff qualifications |
| Safety Reports | SAE, SUSAR, and DSMB reports |
| Monitoring Visit Letters | CRA findings and follow-up items |
| CAPA Plans | Corrective and preventive action documentation |
| Source Documents | Original clinical data records |
| IP Accountability Log | Tracks all IP transactions |
| Financial Disclosure Forms | Conflict-of-interest disclosures |
| IRB Approval Letters | Authorization to conduct research |
| Training | Frequency | Notes |
|---|---|---|
| ICH-GCP Refresher | Annual; Recertification every 2 years | Required by most sponsors and IRBs |
| Protocol-Specific Training | Per study, before any study activities | Document in training log for each protocol |
| EDC System Training | Per system/study | Sponsor-provided for each eCRF platform |
| SOP Reviews | Annually (preferably Q1) | Per PRN SOP PRN_16_01 |
| HIPAA Training | Annual | Required by institutional policy |
| CITI / Human Subjects Protection | Per institutional requirements | Often required before IRB approval |
| ACRP or SOCRA Certification | When eligible | CCRC or CCRP credentials enhance career |
| AE | Adverse Event |
| BLA | Biologics License Application |
| CAPA | Corrective and Preventive Action |
| CFR | Code of Federal Regulations |
| CRF/eCRF | Case Report Form / Electronic CRF |
| DOA | Delegation of Authority |
| DSMB | Data Safety Monitoring Board |
| FDA | Food and Drug Administration |
| GCP | Good Clinical Practice |
| ICH | Int'l Council for Harmonisation |
| IDE | Investigational Device Exemption |
| IND | Investigational New Drug |
| IRB | Institutional Review Board |
| NDA | New Drug Application |
| OHRP | Office for Human Research Protections |
| PMA | Premarket Approval |
| SAE | Serious Adverse Event |
| SUSAR | Suspected Unexpected Serious Adverse Reaction |
| ALCOA+ | Attributable, Legible, Contemporaneous, Original, Accurate (+Complete, Consistent, Enduring, Available) |
| CRA | Clinical Research Associate (Monitor) |
| CRC | Clinical Research Coordinator |
| CRO | Contract Research Organization |
| CTMS | Clinical Trial Management System |
| CVAD | Central Venous Access Device |
| EDC | Electronic Data Capture |
| HIPAA | Health Insurance Portability & Accountability Act |
| ICF | Informed Consent Form |
| IP | Investigational Product |
| LAR | Legally Authorized Representative |
| LTFU | Lost to Follow Up |
| PAT | Protocol Activity Tracker |
| PHI | Protected Health Information |
| PI | Principal Investigator |
| PLC | Provecta Leadership Committee |
| PRN | Provecta Research Network |
Advancing Medicine Through
Excellence in Clinical Research
Clinical Research Coordinator Training Guide — Version 2.0
© 2026 Provecta Research Network. All Rights Reserved.
This document is confidential and intended for internal use only.
provecta.waybook.com